

Claims

1. A method for evaluating the cardiovascular effect of a candidate agent, comprising the steps of:

5 (a) contacting an estrogen receptor-enhanced vascular endothelial cell with a candidate agent; and
(b) determining whether the candidate agent modulates expression of at least one estrogen-regulated marker, wherein the expression of the marker is previously
10 determined to be induced by estrogen in estrogen receptor-enhanced vascular endothelial cells, and therefrom determining whether the candidate agent has a cardiovascular effect.

15 2. A method according to claim 1, wherein the cell is immortalized.

3. A method according to claim 1, wherein step (b) comprises the steps of:

20 (i) detecting a level of an estrogen-regulated marker; and
(ii) comparing the detected level of the estrogen-regulated marker with a level of the estrogen-regulated marker in the absence of the candidate agent.

25 4. A method according to claim 1, wherein step (b) comprises the steps of:

(i) detecting a level of mRNA encoding an estrogen-regulated marker; and
(ii) comparing the detected level of mRNA encoding the
30 estrogen-regulated marker with a level of mRNA encoding the estrogen-regulated marker in the absence of estrogen-related compound.

5. A method according to claim 4, wherein the level of mRNA is detected using an Rnase protection assay.

6. A method according to claim 4, wherein the level of

5 mRNA is detected by:

preparing cDNA from mRNA present within the cell; and
amplifying mRNA encoding the estrogen-regulated marker
via polymerase chain reaction.

10 7. A method according to claim 6, wherein the
amplification is performed using real-time PCR analysis.

8. A method according to claim 1, wherein the cell is
transfected with a polynucleotide comprising a promoter for
15 an estrogen-regulated marker, operably linked to a reporter
gene.

9. A method according to claim 8, wherein step (b)
comprises the steps of:
20 (i) detecting a level of reporter protein activity; and
(ii) comparing the level of reporter protein activity
detected with a level of reporter protein in the absence of
candidate agent.

25 10. A method according to claim 8, wherein step (b)
comprises the steps of:
(i) detecting a level of reporter mRNA; and
(ii) comparing the level of reporter mRNA detected with a
level of reporter mRNA in the absence of estrogen-related
30 compound.

11. A method according to claim 1, wherein the ability of
the candidate agent to modulate expression of at least two
estrogen-regulated markers is determined.

12. A method according to claim 1, wherein the estrogen-regulated marker is selected from the group consisting of SEQ ID NOs:1-74.

5

13. A method for identifying a selective estrogen receptor modulator (SERM), comprising the steps of:

(a) contacting at least two different cells that express an estrogen-regulated marker expression with a candidate SERM;

10 (b) determining levels of expression of at least one estrogen-regulated marker in the cells; and

(c) comparing the levels of expression with levels of expression of the estrogen-regulated marker(s) in cells following contact with estrogen, and therefrom determining
15 whether the candidate SERM is a selective estrogen receptor modulator.

14. A method according to claim 13, wherein the estrogen-regulated marker is selected from the group consisting of
20 SEQ ID NOs:1-74.

15. A method according to claim 13, wherein levels of at least two estrogen-regulated markers are determined.

25 16. A method according to claim 13, wherein each of the cells is independently selected from the group consisting of bone, urogenital, cardiovascular, breast, ovarian, endometrial, and central nervous system cells.

30 17. A method according to claim 13, further comprising the steps of:

(d) contacting breast cells that express an estrogen-regulated marker expression with estrogen and a candidate SERM;

(e) determining levels of expression of at least one estrogen-regulated marker in the breast cells; and
(f) comparing the levels of expression with levels of expression of the estrogen-regulated marker(s) in the breast cells following contact with estrogen, in the absence of candidate SERM.

18. A method for inhibiting the development of a cardiovascular disease in a patient; comprising administering to a patient an agent identified according to the method of claim 1 or a SERM identified according to claim 13.

19. A method for inhibiting the development of breast cancer in a patient; comprising administering to a patient a SERM identified according to the method of claim 17, wherein the SERM inhibits induction of estrogen-regulated marker expression by estrogen in breast cells.

20. A method for inhibiting the development of osteoporosis in a patient; comprising administering to a patient a SERM identified according to claim 13.

21. An isolated or recombinant nucleic acid comprising SEQ ID NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; SEQ ID NO: 59; SEQ ID NO: 60; SEQ ID NO: 61; SEQ ID NO: 62; SEQ ID NO: 63; SEQ ID NO: 64; SEQ ID NO: 65; SEQ ID NO: 66; SEQ ID NO: 67; SEQ ID NO: 68; SEQ ID NO: 69; SEQ ID NO: 70; SEQ ID NO: 71; SEQ ID NO: 72; SEQ ID NO: 73; SEQ ID NO: 74; or SEQ ID NO: 75.

22. An isolated or recombinant nucleic acid that hybridizes under stringent conditions to the nucleic acid of SEQ ID NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; SEQ ID NO: 59; SEQ ID NO: 60; SEQ ID NO: 61; SEQ ID NO: 62; SEQ ID NO: 63; SEQ ID NO:

64; SEQ ID NO: 65; SEQ ID NO: 66; SEQ ID NO: 67; SEQ ID NO:
68; SEQ ID NO: 69; SEQ ID NO: 70; SEQ ID NO: 71; SEQ ID NO:
72; SEQ ID NO: 73; SEQ ID NO: 74; or SEQ ID NO: 75.

23. An isolated or recombinant nucleic acid that is at least
75% identical to at least 50 consecutive nucleic acids of
SEQ ID NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; SEQ ID NO: 59;
SEQ ID NO: 60; SEQ ID NO: 61; SEQ ID NO: 62; SEQ ID NO: 63;
SEQ ID NO: 64; SEQ ID NO: 65; SEQ ID NO: 66; SEQ ID NO: 67;
SEQ ID NO: 68; SEQ ID NO: 69; SEQ ID NO: 70; SEQ ID NO: 71;
SEQ ID NO: 72; SEQ ID NO: 73; SEQ ID NO: 74; or SEQ ID NO:
75.

24. The nucleic acid of claim 23, that is at least 85%
identical to at least 50 consecutive nucleic acids SEQ ID
NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; SEQ ID NO: 59; SEQ ID
NO: 60; SEQ ID NO: 61; SEQ ID NO: 62; SEQ ID NO: 63; SEQ ID
NO: 64; SEQ ID NO: 65; SEQ ID NO: 66; SEQ ID NO: 67; SEQ ID
NO: 68; SEQ ID NO: 69; SEQ ID NO: 70; SEQ ID NO: 71; SEQ ID
NO: 72; SEQ ID NO: 73; SEQ ID NO: 74; or SEQ ID NO: 75.

25. The nucleic acid of claim 24, that is at least 95%
identical to at least 50 consecutive nucleic acids SEQ ID
NO: 56; SEQ ID NO: 57; SEQ ID NO: 58; SEQ ID NO: 59; SEQ ID
NO: 60; SEQ ID NO: 61; SEQ ID NO: 62; SEQ ID NO: 63; SEQ ID
NO: 64; SEQ ID NO: 65; SEQ ID NO: 66; SEQ ID NO: 67; SEQ ID
NO: 68; SEQ ID NO: 69; SEQ ID NO: 70; SEQ ID NO: 71; SEQ ID
NO: 72; SEQ ID NO: 73; SEQ ID NO: 74; or SEQ ID NO: 75.